Natural products as a resource for new drugs

Pharmaceutical Research

Volumn 13, Issue 8, 1996, Pages 1133-1141

  Clark, Alice M ^a  

^a UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; ARTEMETHER; CABERGOLINE; CAMPTOTHECIN; CAPTOPRIL; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; DOCETAXEL; ENALAPRIL; EPIBATIDINE; ERGOTAMINE; ETOPOSIDE; FLUINDOSTATIN; GALANTAMINE; IMMUNOMODULATING AGENT; IRINOTECAN; IVERMECTIN; MEVINOLIN; NALOXONE; NATURAL PRODUCT; NICOTINE; PACLITAXEL; PODOPHYLLOTOXIN; PRAVASTATIN; RETINOID; SIMVASTATIN; TACROLIMUS; TENIPOSIDE; UNINDEXED DRUG;

DRUG DEVELOPMENT; DRUG SCREENING; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANTI-INFECTIVE AGENTS; ANTILIPEMIC AGENTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARDIOVASCULAR AGENTS; CENTRAL NERVOUS SYSTEM AGENTS; PLANT EXTRACTS; PLANTS, MEDICINAL;

EID: 0029739680     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016091631721     Document Type: Review

References (39)

1. D. D. Soejarto and N. R. Farnsworth. Tropical Rain Forests: Potential Source of New Drugs? Perspectives Biol. Med. 32:244-256 (1989).
2. V. E. Tyler, L. R. Brady, and J. E. Robbers. Pharmacognosy, Ninth Edition, Lea & Febiger, Philadelphia, 1988.
3. X.-M. Cheng. To Market, To Market - 1993. In J. A. Bristol (ed.), Annual Reports in Medicinal Chemistry, Academic Press, vol. 29, 1994, pp. 331-354.
4. S. H. Ferreira. A Bradykinin-Potentiating Factor (BPF) Present in the Venom of Bothrops jararaca. Brit. J. Pharmacol. 24:163-169 (1965).
5. S. H. Ferreira, L. J. Greene, V. A. Alabaster, Y. S. Bakhle, and J. R. Vane. Activity of Various Fractions of Bradykinin Potentiating Factor against Angiotensin I Converting Enzyme. Nature 225:379-380 (1970).
6. S. H. Ferreira, D. C. Bartelt, and L. J. Greene. Isolation of Bradykinin-Potentiating Peptides from Bothrops jararaca. Biochem. 9:2583-2593 (1970).
7. M. A. Ondetti, B. Rubin, and D. W. Cushman. Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive Agents. Science 196:441-444 (1977).
8. J. G. Hardman, L. E. Limbird, P. B. Molinoff, R. W. Ruddon, and A. G. Gilman (eds.), The Pharmacological Basis of Therapeutics, Ninth Edition, McGraw-Hill, New York, 1996.
9. R. B. Barlow and H. R. Ing. Curare-Like Action of Polymethylene Bis-Quaternary Ammonium Salts. Brit. J. Pharmacol. Chemother. 3:298 (1948).
10. I. A. McDonald, N. Cosford, and J.-M. Vernier. Nicotinic Acetyl-choline Receptors: Molecular Biology, Chemistry and Pharmacology. In J. A. Bristol (ed.), Annual Reports in Medicinal Chemistry, Academic Press, vol. 30, 1995, pp. 41-50.
11. J. P. Hieble and R. R. Ruffolo. Pharmacology of Neuromuscular Transmission. In P. L. Munson, R. A. Mueller, and G. R. Breese (eds.), Principles of Pharmacology: Basic Concepts & Clinical Applications, Chapman & Hall, New York, 1995, pp. 145-159, 1734.
12. J. Berdy (ed.), CRC Handbook of Antibiotic Compounds. CRC Press, Inc., Boca Raton, Florida, 1980.
13. P. I. Trigg, In , H. Wagner, H. Hikino, and N. R. Farnsworth (eds.), Economic and Medicinal Plant Research, Academic Press, London, vol. 3, 1989, pp. 19-55.
14. Y.-L. Wu and Y. Li. Study on the Chemistry of Qinghaosu (Artemisinin). Med. Chem. Res. 5:569-586 (1995).
15. I.-S. Lee and C. D. Hufford. Metabolism of Antimalarial Sesquiterpene Lactones. Pharmac. Ther. 48:345-355 (1990).
16. H. G. Davies and R. H. Green. Avermectins and Milbemycins. Nat. Prod. Repts. 3:87-121 (1986).
17. K. Awadzi, K. Y. Dadzie, H. Schulz-Key, D. R. W. Haddock, H. M. Gillies, and M. A. Aziz. The Chemotherapy of Onchocerciasis X. An Assessment of Four Single Dose Treatment Regimes of MK-933 (Ivermectin) in Human Onchocerciasis. Ann. Trop. Med. Parasitol 79:63 (1985).
18. B. M. Greene et al. Comparison of Ivermectin and Diethylcarbamazine in the Treatment of Onchocerciasis. New Engl J. Med. 313:133 (1985).
19. S. G. Bradley and F. Marciano-Cabral. Antiparasitic Drugs. In P. L. Munson, R. A. Mueller, and G. R. Breese (eds.), Principles of Pharmacology: Basic Concepts & Clinical Applications, Chapman & Hall, New York, 1995, pp. 1437-1473.
20. T. L. Loo and E. J. Freireich. Cancer Chemotherapeutic Drugs. In P. L. Munson, R. A. Mueller, and G. R. Breese (eds.), Principles of Pharmacology: Basic Concepts & Clinical Applications, Chapman & Hall, New York, 1995, pp. 1475-1516.
21. M. E. Wall and M. C. Wani. Camptothecin and Taxol: Discovery to Clinic - Thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 55:753 (1995).
22. P. B. Schiff, F. Fant, and S. B. Horwitz. Promotion of Microtubule Assembly In Vitro by Taxol. Nature 277:665-667 (1979).
23. M. E. Wall, M. C. Wani, C. E. Cooke, K. H. Palmer, A. T. McPhail, and G. A. Sim. Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata, J. Am. Chem. Soc. 88:388 (1966).
24. H. Sahelin and A. von Wartburg. The Chemical and Biological Route from Podophyllotoxin Glucoside to Etoposide: Ninth Cain Memorial Award Lecture. Cancer Research 51:5-15 (1991).
25. H. Stahelin and A. von Wartburg. In E. Jucker (ed.), Progress in Drug Research, Birkhauser-Verlag, Basel, vol. 33, 1989, pp. 169-266.
26. A. D. Buss and R. D. Waigh. Natural Products as Leads for New Pharmaceuticals. In Manfred E. Wolff (ed.), Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, Vol. 1, John Wiley & Sons, Inc., New York, 1995, pp. 983-1033.
27. G. R. Pettit, C. L. Herald, D. L. Doubek, D. L. Herald, E. Arnold, and J. Clardy. Isolation and Structure of Bryostatin 1. J. Am. Chem. Soc. 104:6846-6848 (1982).
28. R. A. Heyman, D. J. Mangelsdorf, J. A. Dyck, R. B. Stein, G. Eichele, R. M. Evans and C. Thaller. 9-Cis Retinoic Acid Is a High Affinity Ligand for the Retinoid X Receptor. Cell 68:397 (1992).
29. E. A. Allegretto, M. R. McClurg, S. B. Lazarchik, D. L. Clemm, S. A. Kerner, M. G. Elgort, M. F. Boehm, S. K. White, J. W. Pike and R. A. Heyman. Transactivation Properties of Retinoic Acid and Retinoid X Receptors in Mammalian Cells and Yeast. J. Biol. Chem. 268:26625 (1993).
30. A. M Nadzan. Retinoids for the Treatment of Oncological Diseases. In J. A. Bristol (ed.), Annual Reports in Medicinal Chemistry, Academic Press, vol. 30, 1995, pp. 119-128.
31. D. J. Gordon and B. M. Rifkind. 3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors: A New Class of Cholesterol-Lowering Agents. Ann. Int. Med. 107:759-761 (1987).
32. A. G. Brown, T. C. Smale, T. J. King. R. Hasenkamp and R. H. Thompson. Crystal and Molecular Structure of Compactin, A New Antifungal Metabolite from Penicillium brevicompactum. J. Chem. Soc., Perkin Trans. I. 1165-1170 (1976).
33. A. W. Alberts, J. Chen, G. Kuron, V. Hunt, J. Huff, C. Hoffman, J. Rothrock, M. Lopez, H. Joshua, E. Harris, A. Patchett, R. Monaghan, S. Currie, E. Stapley, G. Albers-Schonberg, O. Hensens, J. Hirshfield, K. Hoogsteen, J. Liesch, and J. Springer. Mevinolin: A Highly Potent Competitive Inhibitor of Hydroxy-methylglutaryl-coenzyme A Reductase and a Cholesterol-Lowering Agent. Proc. Natl. Acad. Sci. USA. 77:3957-3961 (1980).
34. A. Ruegger, M. Kuhn, H. Lichti, H. R. Loosli, R. Huguenin, C. Quiquerez, and A. Von Wartburg. Helv. Chim. Acta. 59:1075-1092 (1976).
35. G. S. Noskinm, R. L. Murphy, J. R. Black, and J. P. Phair. Salvage Therapy with Clindamycin/Primaquine for Pneumocystis carinii Pneumonia. Clin. Inf. Dis. 14:183 (1992).
36. Unpublished results.
37. H. Doernenburg and D. Knoor. Strategies for the Improvement of Secondary Metabolite Production in Plant Cell Culture. Enzyme Microb. Technol. 17:674-84 (1995).
38. R. Baum. Combinatorial Chemistry. Chem. Eng. News. 74 (7):28 (1996).
39. L. Katz and S. Donadio. Polyketide Synthesis: Prospects for Hybrid Antibiotics. Annu. Rev. Microbiol. 47:875-912 (1993).